

ANNUAL SCIENTIFIC REPORT 2001 - 2002 ESC WORKING GROUP ON CARDIOVASCULAR PHARMACOLOGY AND DRUG THERAPY (#3)

Nucleus members: E Ambrosioni, J Hampton , F Follath, H Just, W Klein, J Papp, B Prichard, K Stoschitzky, H Sholz , D Van VeldHuisen, M Wehling, F Zannad.

1/ Statement of the objectives of the Working Group

Objectives of the working group on cardiovascular pharmacology and drug therapy are the promotion in European countries of knowledge and teaching of pharmacological properties and therapeutic efficacy of drugs used in cardiovascular-diseases, evaluation of risk-benefit, promotion of methodology of drug effect evaluation, organisation of multicentric clinical trials and epidemiological studies on drug related risk factors (Pharmaco-epidemiology). In addition, objectives of the group are the active participation in production of reference guide-lines and documents on cardiovascular drug use.

2/ Number of sessions organised at the ESC Annual Congress in Berlin 2002

Three sessions have been organised by the group for the 2002 congress in Berlin :

- Acute steroid actions in cardiovascular tissue and their clinical relevance
- How to discover rare serious adverse drug events as early as possible
- Genetic profile : A possibility of improving drug treatment

3/ Activities run outside the ESC Annual Congress

3.1 / Annual meeting of Working Group

The annual meeting of the working group will be held in Monte-Carlo, December 2002, in connection with the ADR (Advanced Drug Research) meeting, held under the auspices of the ESC cardiovascular pharmacology working group. The ADR meeting is organised by Pr Faies Zannad, member of the nucleus of the working group.

The different topics and programm sessions (Chairpersons and speakers) will be finalized during the nucleus meeting at the ESC congress in Berlin.

Proposed topics are :

Cardiovascular problems in Diabetic patients

Epidemiology and management of heart failure

Pharmacogenetics and drug response variability in cardiovascular therapeutics

3.2/ Meeting of the International Society of Cardiovascular Pharmacotherapy

Barcelona , June 2003

Ph. Lechat, as chairman of the working group, is in charge with J Tamargo of the scientific program of this meeting.

All members of the nucleus are asked to participate to the scientific program proposals and fund raising for this meeting.

4/ ESC Task force on documents on beta-blockers and Angiotensin-converting enzyme inhibitors

Several members of the working group (W Klein, P Lechat) have participated to the writing of these two documents.

5/ Membership of the Working Group

The new candidates applying to participate to the working group are as follows :

- Dr Giuseppe Rosano (Roma, Italy)
- Dr Dan Atar (Oslo, Norway)
- Dr Lasse Lehtonen (Espoo, Finland)

Prof. Philippe Lechat

Chairman, Working Group on Cardiovascular Pharmacology and Drug Therapy